

Supplementary Tables

Supplementary Table 1. Patient demographics and baseline characteristics of all available patients receiving a TNFi ≥ 3 months by inclusion status and geographical region

	Overall (n=1475)	Not included (n=835)	Included				
			Total (n=640)	N America (n=176)	EU5 (n=329)	APAC (n=97)	T&ME (n=38)
Age, years							
Mean (SD)	48.9 (11.5)	48.9 (11.5)	48.4 (11.6)	45.8 (12.6)	49.7 (11.5)	48.9 (12.3)	38.6 (5.8)
<65, n (%)	1323 (89.7)	750 (89.8)	573 (89.5)				
Male, n (%)	810 (54.9)	453 (54.3)	357 (55.8)	103 (58.5)	180 (54.7)	57 (58.8)	17 (44.7)
BMI, mean (SD) kg/m²	26.7 (4.7)	27 (4.8)	26.3 (4.6)	28.1 (5.6)	25.9 (3.8)	24.4 (4.6)	26.4 (2.0)
Patient region, n (%)							
N America	462 (31.3)	286 (34.4)	176 (27.5)				
EU5	780 (52.9)	451 (54.0)	329 (51.4)				
APAC	172 (11.7)	75 (9.0)	97 (15.2)				
T&ME	61 (4.1)	23 (2.8)	38 (5.9)				
Time since symptom onset (years)							
	(n=1183)	(n=652)	(n=531)	(n=147)	(n=268)	(n=78)	(n=38)
Mean (SD)	7.9 (7.4)	7.8 (7.4)	7.9 (7.5)	7.8 (6.8)	9.1 (8.0)	6.7 (7.1)	2.1 (1.1)
Time since diagnosis (years)							
	(n=1281)	(n=710)	(n=571)	(n=158)	(n=292)	(n=83)	(n=38)
Mean (SD)	6.2 (6.2)	6.1 (6.0)	6.3 (6.4)	6.4 (6.3)	7.3 (6.8)	5.1 (5.1)	1.3 (1.1)
Presence of psoriasis, n (%)	1421 (96.3)	801 (95.9)	620 (96.9)	172 (97.7)	314 (95.4)	96 (99.0)	38 (100.0)
% BSA psoriasis							
	(n=1118)	(n=620)	(n=498)	(n=148)	(n=228)	(n=84)	(n=38)
Mean (SD)	8.4 (11.4)	7.8 (11.6)	9.1 (11.2)	9.8 (12.5)	(8.7 (9.4)	10.9 (14.4)	4.9 (5.3)
Comorbid fibromyalgia^a							
	(n=1321)	(n=681)	(n=640)	(n=176)	(n=329)	(n=97)	(n=38)
n (%)	53 (4.0)	30 (4.4)	23 (3.6)	8.0 (4.5)	9.0 (2.7)	3.0 (3.1)	3.0 (7.9)
HLA-B27							
	(n=524)	(n=288)	(n=236)	(n=59)	(n=130)	(n=20)	(n=27)
+ve, n (%)	174 (33.2)	82 (28.5)	92 (39.0)	21 (35.6)	40 (30.8)	7 (35.0)	24 (88.9)
Number of TNFiever received, n (%)							

1	1239 (84.0)	706 (84.6)	533 (83.3)	138 (78.4)	268 (81.5)	90 (92.8)	37 (97.4)
2	137 (9.3)	76 (9.1)	61 (9.5)	19 (10.8)	40 (12.2)	2 (2.1)	-
3+	40 (2.7)	22 (2.6)	18 (2.8)	9 (5.1)	6 (1.8)	2 (2.1)	1 (2.6)
Unknown	59 (4.0)	31 (3.7)	28 (4.4)	10 (5.7)	15 (4.6)	3 (3.1)	-
Current severity^a, n (%)							
Mild	1046 (70.9)	611 (73.2)	435 (68.0)	117 (66.5)	210 (63.8)	73 (75.3)	35 (92.1)
Moderate	372 (25.2)	190 (22.8)	182 (28.4)	56 (31.8)	103 (31.3)	22 (22.7)	1 (2.6)
Severe	57 (3.9)	34 (4.1)	23 (3.6)	3 (1.7)	16 (4.9)	2 (2.1)	2 (5.3)
In remission^a, n (%)	846 (57.4)	497 (59.5)	349 (54.5)	70 (39.8)	210 (63.8)	33 (34.0)	36 (94.7)
Disease status^a, n (%)	(n=1467)	(n=828)	(n=639)	(n=176)	(n=328)	(n=97)	(n=38)
Stable/improving	1,352 (92.2)	768 (92.8)	584 (91.4)	154 (87.5)	305 (93.0)	88 (90.7)	37 (97.4)
Unstable/deteriorating	115 (7.8)	60 (7.2)	55 (8.6)	22 (12.5)	23 (7.0)	9 (9.3)	1 (2.6)
Current flare status^a, n (%)	(n=1467)	(n=828)	(n=639)	(n=176)	(n=328)	(n=97)	(n=38)
Never flared	895 (61.0)	522 (63.0)	373 (58.4)	100 (56.8)	182 (55.5)	68 (70.1)	23 (60.5)
Flares, not current	519 (35.4)	277 (33.5)	242 (37.9)	65 (36.9)	138 (42.1)	26 (26.8)	13 (34.2)
Currently flaring	53 (3.6)	29 (3.5)	24 (3.8)	11 (6.3)	8 (2.4)	3 (3.1)	2 (5.3)
ESR	(n=565)	(n=295)	(n=270)	(n=52)	(n=141)	(n=41)	(n=35)
Mean (SD)	15.7 (12.7)	16.0 (13.1)	15.4 (12.2)	18.4 (12.0)	15.0 (12.3)	13.4 (15.6)	15.2 (5.5)
CRP	(n=530)	(n=266)	(n=264)	(n=48)	(n=140)	(n=41)	(n=35)
Mean (SD)	5.0 (7.3)	5.2 (7.5)	4.8 (7.2)	2.7 (4.8)	6.3 (5.9)	3.0 (8.6)	3.7 (11.2)

^aphysician-reported.

Abbreviations: N America, the USA and Mexico; APAC, Asia Pacific Region; BMI, body mass index; BSA, body surface area; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; EU5, Europe; HLA-B27, human leucocyte antigen B27; SD, standard deviation; T&ME, Turkey & the Middle East; TNFi, tumor necrosis factor inhibitor.

Supplementary Table 2. Patient-reported quality of life and societal burden by region

	N America	EU5	APAC	T&ME
	(n=176)	(n=329)	(n=97)	(n=38)
SF-36v2^a, Mean (SD)	(n=176)	(n=326)	(n=95)	(n=38)
Physical Functioning	72.9 (26.5)	71.7 (28.3)	76.8 (22.4)	32.1 (14.4)
Role Physical	75.7 (25.1)	67.0 (28.2)	73.7 (24.7)	55.4 (16.1)
Bodily Pain	66.9 (22.7)	64.9 (25.5)	71.7 (23.1)	46.7 (15.4)
General Health	54.9 (23.4)	47.4 (20.4)	52.4 (19.1)	48.8 (5.5)
Vitality	60.4 (19.7)	52.7 (21.6)	58.1 (18.7)	47.1 (9.5)
Social Functioning	76.7 (23.2)	71.4 (24.5)	75.6 (24.2)	52.3 (14.2)
Role Emotional	79.5 (25.4)	71.6 (27.9)	75.3 (24.5)	51.8 (15.8)
Mental Health	71.1 (19.4)	64.6 (20.3)	66.4 (16.4)	45.9 (8.5)
EQ-5D-3L	(n=171)	(n=322)	(n=94)	(n=38)
Mean (SD)	0.799 (0.255)	0.769 (0.265)	0.853 (0.180)	0.21 (0.263)
EQ-VAS	(n=176)	(n=319)	(n=96)	(n=38)
Mean (SD)	76.6 (16.7)	67.7 (20.1)	70.1 (18.9)	56.8 (11.7)
HAQ-DI	(n=172)	(n=319)	(n=96)	(n=38)
Mean (SD)	0.4 (0.6)	0.7 (0.8)	0.4 (0.6)	1.4 (0.4)
Current employment status among patients of working age, n (%)	(n=154)	(n=270)	(n=83)	(n=38)
Employed/Student/Homemaker	134 (87.0)	213 (78.9)	75 (90.4)	36 (94.7)
Unemployed/retired due to condition	2 (1.3)	20 (7.4)	3 (3.6)	-
Unemployed/retired not due to condition or unspecified	18 (11.7)	37 (13.7)	5 (6.0)	2 (5.3)
WPAI^a, Mean (SD)	(n=107)	(n=141)	(n=54)	(n=17)
% Overall Work Impairment	21.3 (24.6)	26.5 (23.8)	24.8 (21.0)	73.1 (10.1)
% Presenteeism	19.7 (22.8)	22.1 (20.7)	24.3 (20.7)	68.2 (11.9)
% Absenteeism	6.1 (20.1)	9.4 (20.6)	0.8 (2.6)	15.0 (5.6)
WPAI, Mean (SD)	(n=173)	(n=319)	(n=93)	(n=38)
% Activity Impairment	28.3 (26.9)	31.4 (26.7)	27.3 (24.5)	67.9 (11.7)

^aBase varies by domain, minimum base shown.

Abbreviations: N America, the USA and Mexico; APAC, Asia Pacific Region; EQ-5D-3L, 3 level version of 5 dimension EuroQol questionnaire; EQ-VAS, EuroQol visual analogue scale; EU5, Europe; HAQ-DI, Health Assessment Questionnaire Disability Index; SD, standard deviation; SF-36v2, Medical Outcomes Study 36-Item Short-Form version 2; T&ME, Turkey & the Middle East; WPAI, Work Productivity and Activity Impairment questionnaire.